Sarepta Therapeutics
Market Cap
US$6.4b
Last Updated
2019/10/22 23:31 UTC
Data Sources
Company Financials +
Executive Summary
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases.
Snowflake
Fundamentals
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Sarepta Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-2.8%
SRPT
3.1%
US Biotechs
0.07%
US Market
1 Year Return
-36.3%
SRPT
-1.6%
US Biotechs
8.9%
US Market
Return vs Industry: SRPT underperformed the US Biotechs industry which returned -1.6% over the past year.
Return vs Market: SRPT underperformed the US Market which returned 8.9% over the past year.
Shareholder returns
| SRPT | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.8% | 3.1% | 0.07% |
| 30 Day | 3.7% | 0.2% | -0.3% |
| 90 Day | -42.7% | 0.9% | -1.6% |
| 1 Year | -36.3%-36.3% | -0.7%-1.6% | 11.3%8.9% |
| 3 Year | 84.7%84.7% | 18.9%14.7% | 46.3%36.8% |
| 5 Year | 465.8%465.8% | -1.8%-6.6% | 62.1%44.3% |
Price Volatility Vs. Market
How volatile is Sarepta Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?1 month ago | Simply Wall St
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shift From Loss To ProfitValuation
Is Sarepta Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SRPT ($85.55) is trading below our estimate of fair value ($366.34)
Significantly Below Fair Value: SRPT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SRPT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SRPT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SRPT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SRPT is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (2.6x).
Next Steps
Future Growth
How is Sarepta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
71.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: SRPT is forecast to become profitable over the next 3 year, which is considered above average market growth.
High Growth Earnings: SRPT's loss is forecast to worsen by 0% next year.
Revenue vs Market: SRPT's revenue (54.4% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: SRPT's revenue (54.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRPT's Return on Equity is forecast to be low in 3 years time (1%).
Next Steps
Past Performance
How has Sarepta Therapeutics performed over the past 5 years?
-20.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of -20.5% per year.
Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (83.4%).
Return on Equity
High ROE: SRPT has a negative Return on Equity (-51.89%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: SRPT is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: SRPT is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Sarepta Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: SRPT's short term assets ($1.4B) exceeds its short term liabilities ($162.1M)
Long Term Liabilities: SRPT's short term assets (1.4B) exceeds its long term liabilities (486.5M)
Debt to Equity History and Analysis
Debt Level: SRPT's debt to equity ratio (39.2%) is considered satisfactory
Reducing Debt: SRPT's debt to equity ratio has increased from 0.6% to 39.2% over the past 5 years.
Balance Sheet
Inventory Level: SRPT has a low level of unsold assets or inventory.
Debt Coverage by Assets: SRPT's debt is covered by short term assets (assets are 3.311560x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SRPT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SRPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SRPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Sarepta Therapeutics's salary, the management and board of directors tenure and is there insider trading?
1.6yrs
Average management tenure
CEO
Doug Ingram (56yo)
2.3yrs
Tenure
US$1,433,872
Compensation
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 28, 2017. Mr. Ingram serves as Director of Relay Therapeutics, ...
CEO Compensation Analysis
Compensation vs. Market: Doug has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
Management Age and Tenure
1.6yrs
Average Tenure
54yo
Average Age
Experienced Management: SRPT's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Age and Tenure
4.2yrs
Average Tenure
63.5yo
Average Age
Experienced Board: SRPT's board of directors are considered experienced (4.2 years average tenure).
Insider Trading
Insider Buying: SRPT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Non-Employee Director |
| Shares | 5,000 |
| Max Price | US$87.49 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 2,000 |
| Max Price | US$86.74 |
| Entity | Individual |
| Role | Chairman of the Board Chairwoman |
| Shares | 2,500 |
| Max Price | US$87.98 |
| Entity | Individual |
| Role | Member of the Board of Directors Non-Employee Director |
| Shares | 5,000 |
| Max Price | US$99.32 |
| Entity | Individual |
| Role | Member of the Board of Directors Non-Employee Director |
| Shares | 3,700 |
| Max Price | US$122.50 |
| Entity | Individual |
| Role | Member of the Board of Directors Non-Employee Director |
| Shares | 1,300 |
| Max Price | US$122.50 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 16,252 |
| Max Price | US$123.41 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 16,695 |
| Max Price | US$120.94 |
Ownership Breakdown
Management Team
Doug Ingram (56yo)
President
- Tenure: 2.3yrs
- Compensation: US$1.43m
Diane Berry
Senior Vice President of Global Health Policy and Government & Patient Affairs
- Tenure: 0.08yrs
Sandy Mahatme (54yo)
Executive VP
- Tenure: 6.9yrs
- Compensation: US$4.22m
Ty Howton (47yo)
Executive VP
- Tenure: 6.9yrs
- Compensation: US$3.13m
Bo Cumbo (48yo)
Executive VP & Chief Commercial Officer
- Tenure: 3yrs
- Compensation: US$3.12m
Gary Charbonneau
Senior VP of Global Regulatory Affairs
- Tenure: 1.4yrs
Joan Nickerson
Senior Vice President of Human Resources
- Tenure: 0.08yrs
Gilmore O'Neill (54yo)
Executive VP of R&D and Chief Medical Officer
- Tenure: 1.3yrs
- Compensation: US$6.67m
Louise Rodino-Klapac
Senior Vice President of Gene Therapy
- Tenure: 0.6yrs
Ian Estepan
Senior VP of Corporate Affairs & Chief of Staff
- Tenure: 1.8yrs
Board Members
Mike Bonney (61yo)
Director
- Tenure: 1.8yrs
- Compensation: US$445.25k
Doug Ingram (56yo)
President
- Tenure: 2.3yrs
- Compensation: US$1.43m
M. Behrens (67yo)
Chairwoman
- Tenure: 4.5yrs
- Compensation: US$502.15k
Hans Wigzell (81yo)
Chairman of Corporate Strategy Board & Non-Employee Director
- Tenure: 0yrs
- Compensation: US$467.02k
Rick Barry (60yo)
Non-Employee Director
- Tenure: 4.3yrs
- Compensation: US$477.35k
Bev Davidson
Member of Strategic & Scientific Advisory Board
- Tenure: 4.2yrs
Louis Kunkel
Member of Strategic & Scientific Advisory Board
- Tenure: 4.2yrs
Claude Nicaise (66yo)
Non-Employee Director
- Tenure: 4.3yrs
- Compensation: US$464.51k
Kenneth Fischbeck
Member of Strategic & Scientific Advisory Board
- Tenure: 2.6yrs
Matthew Wood
Member of Strategic & Scientific Advisory Board
- Tenure: 2.6yrs
Company Information
Sarepta Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sarepta Therapeutics, Inc.
- Ticker: SRPT
- Exchange: NasdaqGS
- Founded: 1980
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.360b
- Shares outstanding: 74.34m
- Website: https://www.sarepta.com
Number of Employees
Location
- Sarepta Therapeutics, Inc.
- 215 First Street
- Suite 415
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SRPT | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 1997 |
| AB3A | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 1997 |
| 0L35 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 1997 |
Biography
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXO ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/22 23:31 |
| End of Day Share Price | 2019/10/22 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.